These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31959422)

  • 21. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.
    Wan Y; Hickey JM; Bird C; Witham K; Fahey P; Forster A; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Jun; 107(6):1540-1551. PubMed ID: 29421219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mucosal adjuvant for the inactivated poliovirus vaccine.
    Steil BP; Jorquera P; Westdijk J; Bakker WA; Johnston RE; Barro M
    Vaccine; 2014 Jan; 32(5):558-63. PubMed ID: 24333345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
    Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
    J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for the Quality Control of Inactivated Poliovirus Vaccines.
    Wilton T
    Methods Mol Biol; 2016; 1387():279-97. PubMed ID: 26983741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
    Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
    Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urea Improves Stability of Inactivated Polio Vaccine Serotype 3 During Lyophilization and Storage in Dried Formulations.
    Qi W; Orgel S; Francon A; Randolph TW; Carpenter JF
    J Pharm Sci; 2018 Aug; 107(8):2070-2078. PubMed ID: 29709487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
    Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
    Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children.
    Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
    BMJ Open; 2019 Mar; 9(3):e023308. PubMed ID: 30852530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
    Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
    J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
    Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS
    Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.
    Edens C; Dybdahl-Sissoko NC; Weldon WC; Oberste MS; Prausnitz MR
    Vaccine; 2015 Sep; 33(37):4683-90. PubMed ID: 25749246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
    Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
    Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.
    Donadei A; Kraan H; Ophorst O; Flynn O; O'Mahony C; Soema PC; Moore AC
    J Control Release; 2019 Oct; 311-312():96-103. PubMed ID: 31484041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
    Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
    Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine.
    Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB
    Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Oberste MS; Sutter RW; Zaidi AKM
    Vaccine; 2017 May; 35(24):3209-3214. PubMed ID: 28479178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.